Search

Author/Creator Thomas, Christian A

1. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Issue 5 (May 2019)

Authors:
Reck, Martin; Mok, Tony S K; Nishio, Makoto; Jotte, Robert M; Cappuzzo, Federico; Orlandi, Francisco; Stroyakovskiy, Daniil; Nogami, Naoyuki; Rodríguez-Abreu, Delvys; Moro-Sibilot, Denis; Thomas, Christian A; Barlesi, Fabrice; Finley, Gene; Lee, Anthony; Coleman, Shelley; Deng, Yu; Kowanetz, Marc...
Journal:
Lancet
Issue:
Volume 7:Issue 5(2019)
Page Start:
387
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Issue 7 (July 2021)

Authors:
Powles, Thomas; Csőszi, Tibor; Özgüroğlu, Mustafa; Matsubara, Nobuaki; Géczi, Lajos; Cheng, Susanna Y-S; Fradet, Yves; Oudard, Stephane; Vulsteke, Christof; Morales Barrera, Rafael; Fléchon, Aude; Gunduz, Seyda; Loriot, Yohann; Rodriguez-Vida, Alejo; Mamtani, Ronac; Yu, Evan Y; Nam, Kijoeng; Imai...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 7(2021)
Page Start:
931
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search